Condition
Psychosis Not Otherwise Specified
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06740383Recruiting
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
NCT01602029Phase 2Completed
Randomized Double Blind Placebo Control Study in Patients with Schizophrenia
NCT00929955Phase 1Completed
Role of Anti-Inflammatory Agents in Patients With Schizophrenia
NCT01075295Not ApplicableCompleted
Prevention of Weight Gain in Early Psychoses
Showing all 4 trials